As an already approved clinical drug for cancers in the head and neck, stomach, colon and anus, pancreas, lung, cervix, bladder, and breast [129], mitomycin C is expected to be the first practical and economical drug for NRF2-addicted ESCC. Here, NFE2L2 is linked to cancer.